Literature DB >> 27564680

Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy.

Michael Linecker1, Perparim Limani, Patryk Kambakamba, Philipp Kron, Christoph Tschuor, Nicolas Calo, Michelangelo Foti, Jean-François Dufour, Rolf Graf, Bostjan Humar, Pierre-Alain Clavien.   

Abstract

OBJECTIVE: The aim of this study was to assess the effect of Ω3 fatty acids (Ω3FA) on fatty and lean liver in hepatic surgery.
BACKGROUND: The global spread of energy-dense diets has led to an endemic rise in fatty liver disease and obesity. Besides metabolic pathologies, steatosis enhances hepatic sensitivity to ischemia reperfusion (I/R) and impedes liver regeneration (LR). Steatosis limits the application of liver surgery, still the main curative option for liver cancer. Ω3FA are known to reverse steatosis, but how these lipids affect key factors defining surgical outcomes-that is, I/R, LR, and liver malignancy-is less clear.
METHODS: We established a standardized mouse model of high fat diet (HFD)-induced steatosis followed by Ω3FA treatment and the subsequent assessment of Ω3FA effects on I/R, LR, and liver malignancy (n = 5/group), the latter through a syngeneic metastasis approach. Fatty liver outcomes were compared with lean liver to assess steatosis-independent effects. Nonparametric statistics were applied.
RESULTS: Ω3FA reversed HFD-induced steatosis and markedly protected against I/R, improved LR, and prolonged survival of tumor-laden mice. Remarkably, these beneficial effects were also observed in lean liver, albeit at a smaller scale. Notably, mice with metastases in fatty versus lean livers were associated with improved survival.
CONCLUSIONS: Ω3FA revealed multiple beneficial effects in fatty and lean livers in mice. The improvements in I/R injury, regenerative capacity, and oncological outcomes await confirmatory studies in humans.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27564680     DOI: 10.1097/SLA.0000000000001968

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  Omega-3 fatty acids are protective in hepatic ischemia reperfusion injury in the absence of GPR120 signaling.

Authors:  Meredith A Baker; Prathima Nandivada; Paul D Mitchell; Gillian L Fell; Amy Pan; Bennet S Cho; Denis J De La Flor; Lorenzo Anez-Bustillos; Duy T Dao; Vania Nosé; Mark Puder
Journal:  J Pediatr Surg       Date:  2019-04-12       Impact factor: 2.545

2.  Pretreatment with intravenous fish oil reduces hepatic ischemia reperfusion injury in a murine model.

Authors:  Meredith A Baker; Prathima Nandivada; Paul D Mitchell; Gillian L Fell; Amy Pan; Lorenzo Anez-Bustillos; Duy T Dao; Kathleen M Gura; Vania Nosé; Mark Puder
Journal:  Surgery       Date:  2018-01-19       Impact factor: 3.982

Review 3.  Perioperative omega-3 fatty acids for liver surgery: A meta-analysis of randomized controlled trials.

Authors:  Fubin Xiao; Wei Han; Qing Yue; Jianji Ke; Baoxing Jia; Xiaojuan Fu
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

Review 4.  New Insights Into the Role of Autophagy in Liver Surgery in the Setting of Metabolic Syndrome and Related Diseases.

Authors:  Ana Isabel Álvarez-Mercado; Carlos Rojano-Alfonso; Marc Micó-Carnero; Albert Caballeria-Casals; Carmen Peralta; Araní Casillas-Ramírez
Journal:  Front Cell Dev Biol       Date:  2021-06-01

Review 5.  Computational Modeling in Liver Surgery.

Authors:  Bruno Christ; Uta Dahmen; Karl-Heinz Herrmann; Matthias König; Jürgen R Reichenbach; Tim Ricken; Jana Schleicher; Lars Ole Schwen; Sebastian Vlaic; Navina Waschinsky
Journal:  Front Physiol       Date:  2017-11-14       Impact factor: 4.566

6.  The 150 most important questions in cancer research and clinical oncology series: questions 76-85 : Edited by Chinese Journal of Cancer.

Authors: 
Journal:  Chin J Cancer       Date:  2017-11-20

7.  Omega-3 fatty acid supplementation does not influence liver regeneration in rats after partial hepatectomy.

Authors:  Mohammad Akbari; Suleyman Utku Celik; Akin Firat Kocaay; Omer Arda Cetinkaya; Seher Demirer
Journal:  Clin Exp Hepatol       Date:  2018-12-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.